3320'un PE Oranı emsallerine kıyasla nasıldır?

3320 is good value based on its Price-To-Earnings Ratio (8.5x) compared to the peer average (12.4x).

3320'nin PE Oranı, HK Pharmaceuticals Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

3320 is expensive based on its Price-To-Earnings Ratio (8.5x) compared to the Hong Kong Pharmaceuticals industry average (8.2x).

3320'nin PE Oranı, Adil PE Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PE Oranıdır.

3320 is good value based on its Price-To-Earnings Ratio (8.5x) compared to the estimated Fair Price-To-Earnings Ratio (12.1x).

Gelecekteki nakit akışlarına bakıldığında 3320 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

3320 (HK$5.62) is trading below our estimate of [[fair value]] (HK$21.16)

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

China Resources Pharmaceutical Group (SEHK:3320) - Hisse Senedi Fiyatı, Haberler ve Analizler

3320 Stoklara Genel Bakış

Şirket hakkında

3320 temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	5/6
Finansal Sağlık	5/6
Temettüler	2/6

Ödüller

Trading at 73.4% below our estimate of its fair value

Earnings are forecast to grow 7.46% per year

Earnings grew by 11.7% over the past year

Risk Analizi

Has a high level of debt

China Resources Pharmaceutical Group Limited Rakipler

CSPC Pharmaceutical Group

SEHK:1093

HK$61.4b

United Laboratories International Holdings

SEHK:3933

HK$19.5b

Grand Pharmaceutical Group

SEHK:512

HK$16.1b

Sino Biopharmaceutical

SEHK:1177

HK$65.5b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti China Resources Pharmaceutical Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$5.62
52 Haftanın En Yüksek Seviyesi	HK$7.11
52 Haftanın En Düşük Seviyesi	HK$4.45
Beta	0.39
11 Aylık Değişim	-14.98%
3 Aylık Değişim	3.12%
1 Yıllık Değişim	12.63%
33 Yıllık Değişim	58.76%
5 Yıllık Değişim	-20.40%
Halka arzdan bu yana değişim	-37.62%

Son Haberler & Güncellemeler

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Oct 07

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Aug 30

Recent updates

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Oct 07

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Aug 30

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Jun 01

Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

May 13

China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

Apr 28

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Apr 14

China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

Mar 28

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

Jan 28

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Dec 06

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Sep 07

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

Aug 02

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

May 26

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

May 05

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 04

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Jan 24

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Dec 15

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

Oct 18

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

Aug 27

China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

May 29

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

May 02

China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

Apr 07

China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Mar 31

Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Feb 21

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Dec 07

China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

Nov 10

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Aug 29

Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Aug 03

Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

May 03

Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Apr 12

Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 17

Hissedar Getirileri

	3320	HK Pharmaceuticals	HK Pazar
7D	-2.4%	-7.2%	-1.0%
1Y	12.6%	-2.9%	15.0%

Getiri vs. Endüstri: 3320 exceeded the Hong Kong Pharmaceuticals industry which returned -2.9% over the past year.

Getiri vs Piyasa: 3320 underperformed the Hong Kong Market which returned 15% over the past year.

Fiyat Oynaklığı

Is 3320's price volatile compared to industry and market?
3320 volatility
3320 Average Weekly Movement	6.8%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.3%

İstikrarlı Hisse Senedi Fiyatı: 3320 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Zaman İçindeki Volatilite: 3320's weekly volatility (7%) has been stable over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2007	72,764	Xiaosong Bai	www.crpharm.com

Bir yatırım holding şirketi olan China Resources Pharmaceutical Group Limited, Çin Anakarası'nda ve uluslararası alanda ilaç ve diğer sağlık ürünlerinin araştırma ve geliştirme, üretim, dağıtım ve perakende satışını yapmaktadır. Dört segmentte faaliyet göstermektedir: İlaç Üretimi, İlaç Dağıtımı, İlaç Perakendeciliği ve Diğerleri. Şirket, kardiyovasküler ve serebrovasküler, sindirim sistemi, metabolizma ve endokrin, solunum, ortopedi, onkoloji, tıbbi beslenme, gastroenteroloji, pediatri, genitoüriner sistem, öksürük ve soğuk algınlığı, anti-enfeksiyon, dermatoloji, infüzyon çözümleri vb.

China Resources Pharmaceutical Group Limited Temel Bilgiler Özeti

China Resources Pharmaceutical Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
3320 temel i̇stati̇sti̇kler
Piyasa değeri	HK$34.81b
Kazançlar(TTM)	HK$4.14b
Gelir(TTM)	HK$274.62b

8.5x

F/K Oranı

0.1x

P/S Oranı

3320 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
3320 gelir tablosu (TTM)
Gelir	CN¥250.48b
Gelir Maliyeti	CN¥210.97b
Brüt Kâr	CN¥39.51b
Diğer Giderler	CN¥35.73b
Kazançlar	CN¥3.78b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.60
Brüt Marj	15.77%
Net Kâr Marjı	1.51%
Borç/Özkaynak Oranı	77.1%

3320 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

3.2%

Mevcut Temettü Verimi

39%

Ödeme Oranı

3320 Stoklara Genel Bakış

Ödüller

Risk Analizi

China Resources Pharmaceutical Group Limited Rakipler

SEHK:1093

HK$61.4b

SEHK:3933

HK$19.5b

SEHK:512

HK$16.1b

SEHK:1177

HK$65.5b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New minor risk - Dividend sustainability

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 18%

Upcoming dividend of HK$0.091 per share

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

New minor risk - Financial position

Recent updates

New minor risk - Dividend sustainability

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 18%

Upcoming dividend of HK$0.091 per share

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

New minor risk - Financial position

First half 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.45 in 1H 2023)

China Resources Pharmaceutical Group Limited Announces Resignation of Bai Xiaosong as Chief Executive Officer

China Resources Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 29, 2024

China Resources Pharmaceutical Group Limited Announces Directorate Changes

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

China Resources Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.17 per share

Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

Investor sentiment improves as stock rises 17%

China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

Full year 2023 earnings: EPS and revenues miss analyst expectations

Now 20% overvalued

China Resources Pharmaceutical Group Limited Announces Change of Company Secretary

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

China Resources Dong-E-E-Jiao Company Limited Provides Earnings Guidance for the Three Months Ended 31 March 2024

Now 21% overvalued

China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

Dividend of HK$0.17 announced

China Resources Pharmaceutical Group Limited, Annual General Meeting, May 30, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

China Resources Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 19 July 2024

China Resources Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

China Resources Pharmaceutical Group Limited Announces Management Changes, Effective on 27 December 2023

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: HK$0.48 (vs HK$0.48 in 1H 2022)

China Resources Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 31, 2023

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

New minor risk - Dividend sustainability

China Resources Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

China Resources Pharmaceutical Group Limited Announces Executive Changes

China Resources Pharmaceutical Group Limited Approves to Declare A Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.16 per share at 2.1% yield

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

Price target increased by 7.6% to HK$7.97

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Price target increased by 8.9% to HK$7.60

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2022 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued

Now 22% undervalued

China Resources Pharmaceutical Group Limited Announces Appointment of Non-Executive Director

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Less than half of directors are independent

Investor sentiment improved over the past week

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

China Resources Pharmaceutical Group Limited Announces Retirement of Mr. Tan Ying as Non-Executive Director

First half 2022 earnings released: EPS: HK$0.48 (vs HK$0.39 in 1H 2021)

China Resources Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 25, 2022

China Resources Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022